Jazz Pharmaceuticals highlights Ziihera launch, targets $3-$5 billion zanidatamab peak sales opportunity

Reuters2026/08/26 09:22

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jazz Pharmaceuticals highlighted the US commercial launch of Ziihera (zanidatamab-hrii) for first-line HER2-positive advanced gastroesophageal adenocarcinoma.
Label supports use with fluoropyrimidine-platinum chemotherapy with tislelizumab for IHC 3+ or IHC 2+/ISH+ disease, regardless of PD-L1 status.
Median overall survival was 26.4 months for Ziihera-chemotherapy-tislelizumab versus 19.2 months for trastuzumab-chemotherapy; p=0.0043.
Median progression-free survival was 12.4 months versus 8.1 months; objective response rate was 67% versus 63%.
Presentation reiterated a $3 billion-$5 billion peak sales opportunity for zanidatamab across gastroesophageal, biliary tract, breast, and other HER2-expressing cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Jazz Pharmaceuticals highlights Ziihera launch, targets $3-$5 billion zanidatamab peak sales opportunity

You may also like

Crypto prices